VIDEX EC (didanosine) is a Nucleoside Reverse Transcriptase Inhibitor (NRTI) drug that is used in combination with other antiretroviral medications that is used for the treatment of HIV.
Dosing & Administration
VIDEX EC is indicated for HIV positive adults, children, and infants. However, caution should be used in infants younger than three months old. VIDEX EC in pill form cannot be crushed, chewed or opened as it is in an extended-release “gastro-resistant” capsule. It also comes in as an oral liquid. It is recommended that VIDEX EC be taken on an empty stomach, but recent studies have suggested that it may be taken with or without food. Read the product insert for additional dosage details.
As outlined in the package insert, dosing adjustments are required for any degree of renal dysfunction. This drug should be used with extreme caution for those with risk factors for liver disease and with liver dysfunction. Safety and efficacy for patients with underlying liver disease has not been established.
VIDEX EC is contraindicated in patients taking stavudine and with hypersensitivity to the drug. Further details are available in the package insert.
Possible side effects of VIDEX EC are optic nerve lesions, pancreatitis, hepatotoxicity, peripheral neuropathy, non-cirrhotic portal hypertension, osteonecrosis, immune reactivation syndrome, and lipoatrophy. Further side effects are provided in the package insert.
VIDEX EC has a warning of its association with hepatotoxicity or lactic acidosis. Risk factors are being female, obesity, and prolonged therapy. VIDEX EC cautions against using this drug if the patient has a history of pancreatitis or is taking medications with a known association with pancreatitis. There is a high mortality rate linking VIDEX EC and lactic acidosis and hepatomegaly with steatosis. Details are available in the package insert detail appropriate screening and monitoring recommendations.
Patients should be screened for myocardial infarction as there is an increased risk with VIDEX EC.
HIV positive patients should be screened for a comorbid Hepatitis B virus (HBV) and Hepatitis C virus (HCV) infection. If co-infected, patients should be started on an antiretroviral regimen targeting co-infected viruses, regardless of CD4 counts or viral loads. Drug regimens and prescribing considerations are detailed in the current HIV treatment guidelines.
VIDEX EC is associated with possible herbal interactions and drug-to-drug interactions and contraindications. Details are listed in the package insert.
Pregnancy & Lactation
Since VIDEX EC is teratogenic, current guidelines should be investigated when treating women who are pregnant. As it is unknown if VIDEX EC is transmitted through breast milk, it is recommended that breastfeeding be avoided in HIV positive women.
In the case of an overdose, standard supportive treatment and close monitoring should be used, as there is no known antidote for a VIDEX EC overdose. so. Didanosine is partially dialyzed.
Reviews are only written by verified customers who have purchased this product.